We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Blood Clotting Proteins Discovered as Biomarkers of Lupus Nephritis
News

Blood Clotting Proteins Discovered as Biomarkers of Lupus Nephritis

Blood Clotting Proteins Discovered as Biomarkers of Lupus Nephritis
News

Blood Clotting Proteins Discovered as Biomarkers of Lupus Nephritis

Professor of biomedical engineering Chandra Mohan reports that clotting proteins are elevated in the urine of patients with lupus nephritis. Credit: University of Houston
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Blood Clotting Proteins Discovered as Biomarkers of Lupus Nephritis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

University of Houston researcher Chandra Mohan is reporting in Arthritis Research and Therapy that clotting proteins, both those that promote blood clots (pro-thrombotic) and those that work to dissipate them (thrombolytic), are elevated in the urine of patients who suffer from lupus nephritis (LN).

“Among the proteins examined, urine plasmin emerged as the strongest independent predictor of kidney function and renal disease status,” reports Mohan, Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering. “Urine biomarkers represent promising candidates for the early diagnosis as well as the monitoring of disease activity and therapeutic responses in lupus nephritis.” The discovery of the new biomarker for active LN opens the door for clinical monitoring of the disease.

Systemic lupus erythematosus (SLE) is an autoimmune disease that occurs when the body attacks its own tissues and organs. Inflammation from the disease can impact many different parts of the body including joints, skin, kidneys, blood cells, brain and heart. Lupus nephritis is one of the most frequent and severe clinical manifestations of SLE, representing a leading cause of morbidity and mortality.

New immunosuppressive drugs and biologics have brought improvements in recent SLE and LN survival rates, but early diagnosis and monitoring disease flares are still challenges that need to be addressed. Renal biopsy remains the gold standard for the diagnosis and prognosis of LN, but it’s invasive and cannot be used for routine monitoring of disease activity and treatment responses. Because of this, several studies focusing on screening and identifying non-invasive biomarkers for the early diagnosis and monitoring of SLE and LN are emerging.

Because coagulation system disorders have been reported in SLE and lupus nephritis patients and the frequency of thrombotic events was documented to be higher in SLE patients than in the general population, Mohan’s lab examined urinary proteins related to coagulation.

Finding elevations in both pro-thrombotic and thrombolytic proteins in the urine of patients with lupus nephritis was unexpected.

“When I first saw the presence of both I thought ‘This can’t be right, so let’s look at this in more detail with more urine samples and better assays,’” said Mohan, who describes the presence of both proteins as “a raging war” within the kidneys. If one or the other predominates, he said, there are medicines that can regulate the clotting in balance, but when both processes are equally upregulated, balancing this biological process becomes clinically challenging.

Urine samples for this study were obtained from 113 patients with LN who had previously been recruited from the renal clinic at UT Southwestern Medical Center between 2007 and 2011. Collaborating with Mohan on the study are lead author, Qing Ling, a practicing nephrologist, Michelle A. Petri, director of the Hopkins Lupus Center at Johns Hopkins Medicine, Baltimore, and Ramesh Saxena, professor of internal medicine –nephology at UT Southwestern Medical Center, Dallas.

Reference: Qin, L., Stanley, S., Ding, H., Zhang, T., Truong, V., & Celhar, T. et al. (2019). Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis. Arthritis Research & Therapy, 21(1). doi: 10.1186/s13075-019-1959-y

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement